Latest lower respiratory tract infection Stories

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. Bronchiectasis is characterized by abnormal widening of the bronchi (air tubes that branch deep into the lungs) and can cause recurrent lung infections, a disabling cough, shortness of breath, and coughing up blood. "If...

GAITHERSBURG, Md., May 3, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program. The SBIR grant, valued at approximately $590,000, will provide funding to further understand the impact of maternal...

GAITHERSBURG, Md., March 23, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012. The poster titled "Respiratory Syncytial Virus Neutralizing Antibodies Induced by Recombinant Adenovirus Vectors" #116 was presented on March 22, 2012 in Poster...

Pneumonia and other lower respiratory tract infections are the second most common infections among nursing home residents and the leading cause of death from infections in the long-term care setting HARRISBURG, Pa., Dec. 1, 2011 /PRNewswire-USNewswire/ -- The reported number of lower respiratory tract infections (LRTIs) and influenza-like illnesses (ILIs) increased by six percent and 28 percent respectively in Pennsylvania nursing homes in 2011 compared to 2010 data, emphasizing the...

Immunization, including flu vaccine, can thwart pneumonia in children, guidelines suggest Immunizations, including a yearly flu vaccine, are the best way to protect children from life-threatening pneumonia, according to new guidelines from the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA). The guidelines, which are the first on diagnosing and treating community-acquired pneumonia (CAP) in infants and children, place preventing...

Study shows need for judicious use of drugs to curb antibiotic resistanceShort courses of antibiotics appear just as effective as longer ones "” and a great deal safer "” in treating respiratory infections that might cause pneumonia in children on temporary breathing devices, according to a Johns Hopkins Children's Center study published online May 3 in Clinical Infectious Diseases.In the study's analysis of 150 children treated with antibiotics for respiratory infections while on a...

ROCKVILLE, Md., Jan. 4, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has begun patient enrollment in a Phase I clinical trial to assess the safety, immunogenicity and tolerability of a vaccine candidate against respiratory syncytial virus (RSV). In this blinded, placebo-controlled, escalating-dose study of healthy adults 18 to 49 years old, a total of 100 subjects will be allocated to four cohorts and randomized to receive vaccine treatment or saline placebo in...

ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle (VLP) vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge. This vaccine candidate has been created with technology that Novavax has licensed...

GAITHERSBURG, Md., June 2 /PRNewswire/ -- MedImmune today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants. The committee's recommendation will be considered by FDA reviewers in their evaluation of the Biologics License Application (BLA) for motavizumab. "We...

GAITHERSBURG, Md., May 3 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that researchers will present results from five studies in the areas of respiratory syncytial virus (RSV) at the 2010 Pediatric Academic Societies (PAS) annual meeting taking place May 1-4, 2010 in Vancouver, BC, Canada. MedImmune abstracts to be presented at PAS regarding RSV include: Respiratory syncytial virus (RSV) Hospitalization in infants with Chronic Lung Disease (CLD): An...